ArticleClinical imaging2023
Rate of benign nodule resection in a lung cancer screening program.
Article in Clinical imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- Noninvasive differentiation of benign and malignant solid pulmonary nodules using multiparameter dual-layer spectral CT radiomics.Insights into imaging · 2026Article
- Improving lung cancer screening diagnostic efficiency.Current opinion in pulmonary medicine · 2026Review
- Diagnostic Yield and Safety of Radial Probe Endobronchial Ultrasound-Guided Transbronchial Lung Cryobiopsy with a Guide Sheath in Pulmonary Lesions < 3 cm.Diagnostics (Basel, Switzerland) · 2026Article
- The Stockholm Pilot study for Lung cancer Screening (Stockholm PLUS): feasibility of baseline low-dose CT lung cancer screening in a high-risk Swedish female population.Acta oncologica (Stockholm, Sweden) · 2026Article
- Management of suspicious nodules in lung cancer screening - a narrative review of monitoring strategies based on nodule features and further needs.Frontiers in oncology · 2026Review
- AI-assisted clinico-quantitative imaging nomogram for preoperative malignancy risk in solid and part-solid pulmonary nodules ≤ 3 cm: development and internal validation.Frontiers in oncology · 2026Article
- Biopsy-Proven Pulmonary Tumors Detected by LDCT: A 10-Year Single-Center Study of Growth Patterns and Diagnostic Pitfalls.International journal of medical sciences · 2026Article
- Monitoring the Harms of Lung Cancer Screening: Why the Nonmalignant Resection Rate Is Our Best Bet.Journal of the American College of Radiology : JACR · 2025Article
- Article
- Leveraging technology to help the patient: Combined robotic bronchoscopic biopsy with surgical resection during the same anesthetic event.JTCVS techniques · 2025Article
- Integrated metabolomic, transcriptomic and network analysis elucidates therapeutic mechanisms ofFrontiers in pharmacology · 2025Article
- Blood microRNA testing in participants with suspicious low-dose CT findings: follow-up of the BioMILD lung cancer screening trial.The Lancet regional health. Europe · 2024Article
- Value of CT diagnostic techniques based on imaging post-processing systems in the early diagnosis and treatment of lung cancer.American journal of translational research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
purposeScreening with low dose computed tomography (CT) can reduce lung cancer related death at the expense of unavoidable false positive results. The purpose of this study is to measure the rate of surgery for benign nodules, and evaluate characteristics of those nodules. MATERIALS AND
methodsIn this study, we evaluated patients in the Lung Cancer Screening (LCS) program across a large tertiary healthcare network from 5/2015 through 10/2021 who underwent surgical resection for a lung nodule. We reviewed the pathology reports and subsequent follow-up to establish whether the nodule was benign or malignant. Imaging characteristics of the nodules were evaluated by a radiology fellow, and we recorded Lung-RADS category, nodule status (baseline, stable, new, growing), FDG uptake on PET/CT, and calculated the risk from the Brock model.
resultsDuring this time period, a total of 21,366 LCS CT was performed in 9050 patients, and 260 patients underwent a following surgical resection. Review of the pathology results revealed: 220 lung cancer (85%), 2 other malignancies (1%), and 38 benign findings (15%). Pathology of the benign nodules was as follows: 12 with scarring/fibrosis, 5 with benign neoplasms, 14 with infection/inflammation, and 7 with other diagnoses. Lung-RADS category was as follows: 4 (11%) Lung-RADS 2, 2 (5%) Lung-Rad 3, 11 (29%) Lung-RADS 4A, 13 (34%) Lung-RADS 4B, and 8 (21%) Lung-RADS 4X. The size of the nodules ranged from 4 to 41 mm with a median of 13 mm. 2 (5%) were ground glass, 10 (26%) were part-solid, and 26 (68%) were solid. FDG-PET/CT was performed in 19 out of 38 cases, of which: 2 (11%) had no uptake, 10 (53%) had mild uptake, 3 (16%) had moderate uptake, and 4 (21%) had intense uptake. Risk assessment by Brock calculator revealed that 9 (24) had <5% (very low) risk; 27 (71%) had 5-65% (low-intermediate) risk, and 2 (5%) had >65% (high) risk.
conclusionSurgical resection of benign nodules is unavoidable despite application of Lung-RADS guidelines in a modern screening program, with approximately 15% of surgeries being done for benign lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.